Patents by Inventor Blanka Zelezna
Blanka Zelezna has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10751390Abstract: Lipidated neuropeptides PrRP31, PrRP20, containing C14 to C16 fatty acid, and their analogs, wherein a sequence of IRPVGRF-NH2 at the C-terminus is variable in the site of isoleucine, valine and phenylalanine; said fatty acid is bound in position 1 or 11 for PrRP31 or its analog and in position 1 or 7 for PrRP20 or its analog; the bond comprises an amide bond between an amino acid having at least one free NH2 group and a carboxylic group of the fatty acid and alternatively includes also a binding through arm X2, which is a hydrophilic linker selected from a group comprising ?-alanine, ?-aminobutyric acid or ?-glutamic acid; for use in the treatment and prevention of diseases, which are Alzheimer's disease (AD), Parkinson's disease (PD), cognitive impairment no dementia (CIND), brain trauma, and neurodegenerative changes and disorders.Type: GrantFiled: August 26, 2019Date of Patent: August 25, 2020Assignee: USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I.Inventors: Lenka Maletinska, Blanka Zelezna, Miroslava Blechova, Andrea Spolcova, Barbora Mikulaskova, Jaroslav Kunes, Stepan Strnad
-
Publication number: 20200016240Abstract: Lipidated neuropeptides PrRP31, PrRP20, containing C14 to C16 fatty acid, and their analogs, wherein a sequence of IRPVGRF-NH2 at the C-terminus is variable in the site of isoleucine, valine and phenylalanine; said fatty acid is bound in position 1 or 11 for PrRP31 or its analog and in position 1 or 7 for PrRP20 or its analog; the bond comprises an amide bond between an amino acid having at least one free NH2 group and a carboxylic group of the fatty acid and alternatively includes also a binding through arm X2, which is a hydrophilic linker selected from a group comprising ?-alanine, ?-aminobutyric acid or ?-glutamic acid; for use in the treatment and prevention of diseases, which are Alzheimer's disease (AD), Parkinson's disease (PD), cognitive impairment no dementia (CIND), brain trauma, and neurodegenerative changes and disorders.Type: ApplicationFiled: August 26, 2019Publication date: January 16, 2020Applicant: USTAV ORGANICKE CHEME A BIOCHEMIE AV CR, V.V.I.Inventors: Lenka Maletinska, Blanka Zelezna, Miroslava Blechova, Andrea Spolcova, Barbora Mikulaskova, Jaroslav Kunes, Stepan Strnad
-
Patent number: 10350271Abstract: Lipidated analogs of prolactin-releasing peptides (PrRP) and their use in controlling and lowering blood glucose in mammals is disclosed. Useful compounds included lipidated analogs of PrRP20 and PrRP31. Pharmacological effects are demonstrated both in vitro and in vivo. Peripheral administration of the lipidated peptides towers blood glucose levels. These treatments are applicable for treating impaired glucose tolerance (IGT), and glucose intolerance condition. The disclosed compounds have application in treating medical conditions including diabetes, pre-diabetes, eating disorders, and obesity.Type: GrantFiled: April 26, 2016Date of Patent: July 16, 2019Assignees: USTAV ORGANICKE CHEMIE A BIOCHEMIE AKADEMIE VED CR, V.V.I., FYZIOLOGICKY USTAV AKADEMIE VED CR, V.V.I.Inventors: Lenka Maletinska, Blanka Zelezna, Jaroslav Kunes, Veronika Prazienkova
-
Patent number: 9937235Abstract: Lipidated peptides, analogs of both forms of the prolactin-releasing peptide, PrRP31 and PrRP20, represent anorexigenic compounds that lower food intake and function in the brain after peripheral administration. The analogs PrRP31 and PrRP20 lipidated at the N-terminus by myristic or palmitic acids bind with high affinity to the endogenous receptor GPR10 in the rat pituitary cell line RC-4B/C and CHO cell line with transfected human receptor. These lipidated peptides also significantly decrease, in a dose-dependent manner, the food intake in fasted mice and have similar effects in comparable doses as centrally administered natural PrRP31, these effects are, however, stronger and longer lasting. Lipidation of an effective anorexigenic neuropeptide PrRP induces a central effect after peripheral administration and thus makes the lipidated analogs of PrRP a promising anti-obesity drug.Type: GrantFiled: July 11, 2013Date of Patent: April 10, 2018Assignee: USTAV ORGANICKE CHEMIE A BIOCHEMIE AKADEMIE VED CR, V.V.I.Inventors: Lenka Maletinska, Blanka Zelezna, Miroslava Blechova, Andrea Popelova
-
Publication number: 20170051031Abstract: Lipidated neuropeptides based on PrRP31, PrRP20, containing C14 and/or C16 fatty acid, in which sequence of IRPVGRF-NH2 at the C-terminus is variable in the site of isoleucine, valine and phenylalanine; the fatty acid is bound in position 1 or 11 for PrRP31 or its analog and in position 1 or 7 for PrRP20 or its analog; the fatty acid is bound directly or through a hydrophilic linker X2, for use in the treatment and prevention of neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), cognitive impairment no dementia (CIND), brain trauma, and neurodegenerative changes and disorders.Type: ApplicationFiled: May 20, 2015Publication date: February 23, 2017Applicant: USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I.Inventors: Lenka MALETINSKA, Blanka ZELEZNA, Miroslava BLECHOVA, Andrea SPOLCOVA, Barbora MIKULASKOVA, Jaroslav KUNES
-
Publication number: 20170044230Abstract: The present invention provides long-acting stable peptide ghrelin analogs of general formulae (I) (Sar)S(Dpr-X1)mLSPEHQKAQQRKESKKPPA(K-Z)LQPR,? and/or (II) (Sar)S(Dpr-X2)FLSPEHQKAQQR(K-Z)ES, in which Dpr is diaminopropionic acid, Sar is sarcosin, X1 represents a fatty acid residue selected from the group comprising octanoyl, decanoyl, myristoyl, 9-decenoyl and N-10-undecynoyl bound to Dpr through an amide bond, X2 represents decanoyl or myristoyl, m represents a non-coded amino acid selected from the group comprising phenylalanine, naphtylalanine, cyclohexylalanine, t-butylalanine and dichlorophenylalanine, Z is palmitoyl which can be optionally bound to the secondary amino group of lysine through an amide bond or Z is not present. The compounds of the invention are suitable for use in a method of treatment of cachexia and/or anorexia.Type: ApplicationFiled: June 22, 2015Publication date: February 16, 2017Applicants: USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I., FYZIOLOGICKY USTAV AV CR, V.V.I.Inventors: Lenka MALETINSKA, Blanka ZELEZNA, Jaroslav KUNES, Martina HOLUBOVA, Jana ZEMENOVA
-
Publication number: 20160331812Abstract: Lipidated peptides, analogs of both forms of the prolactin-releasing peptide. PrRP31 and PrRP20, represent anorexigenic compounds that lower food intake and function in the brain after peripheral administration. The analogs PrRP31 and PrRP20 lipidated at the N-terminus by myristic or palmitic acids bind with high affinity to the endogenous receptor GPR10 in the rat pituitary cell line RC-4B/C and CHO cell line with transfected human receptor. These lipidated peptides also significantly decrease, in a dose-dependent manner, the food intake in fasted mice and have similar effects in comparable doses as centrally administered natural PrRP31, these effects are, however, stronger and longer lasting. Lipidation of an effective anorexigenic neuropeptide PrRP induces a central effect after peripheral administration and thus makes the lipidated analogs of PrRP a promising anti-obesity drug.Type: ApplicationFiled: April 8, 2016Publication date: November 17, 2016Applicant: USTAV ORGANICKE CHEMIE A BIOCHEMIE AKADEMIE VED CR, V.V.IInventors: Lenka MALETINSKA, Blanka ZELEZNA, Miroslava BLECHOVA, Andrea POPELOVA
-
Publication number: 20160228563Abstract: Lipidated analogs of prolactin-releasing peptides (PrRP) and their use in controlling and lowering blood glucose in mammals is disclosed. Useful compounds included lipidated analogs of PrRP20 and PrRP31. Pharmacological effects are demonstrated both in vitro and in vivo. Peripheral administration of the lipidated peptides towers blood glucose levels. These treatments are applicable for treating impaired glucose tolerance (IGT), and glucose intolerance condition. The disclosed compounds have application in treating medical conditions including diabetes, pre-diabetes, eating disorders, and obesity.Type: ApplicationFiled: April 26, 2016Publication date: August 11, 2016Applicants: USTAV ORGANICKE CHEMIE A BIOCHEMIE AKADEMIE VED CR, V.V.I., FYZIOLOGICKY USTAV AKADEMIE VED CR, V.V.I.Inventors: LENKA MALETINSKA, Blanka Zelezna, Jaroslav Kunes, Veronika Prazienkova
-
Publication number: 20150196651Abstract: Lipidated analogs of prolactin-releasing peptides (PrRP) and their use in controlling and lowering blood glucose in mammals is disclosed. Useful compounds included lipidated analogs of PrRP20 and PrRP31. Pharmacological effects are demonstrated both in vitro and in vivo. Peripheral administration of the lipidated peptides lowers blood glucose levels. These treatments are applicable for treating impaired glucose tolerance (IGT), and glucose intolerance condition. The disclosed compounds have application in treating medical conditions including diabetes, pre-diabetes, eating disorders, and obesity.Type: ApplicationFiled: January 15, 2015Publication date: July 16, 2015Inventors: Lenka MALETINSKA, Blanka ZELEZNA, Jaroslav KUNES, Veronika NAGELOVA
-
Publication number: 20150175674Abstract: Lipidated peptides, analogs of both forms of the prolactin-releasing peptide, PrRP31 and PrRP20, represent anorexigenic compounds that lower food intake and function in the brain after peripheral administration. The analogs PrRP31 and PrRP20 lipidated at the N-terminus by myristic or palmitic acids bind with high affinity to the endogenous receptor GPR10 in the rat pituitary cell line RC-4B/C and CHO cell line with transfected human receptor. These lipidated peptides also significantly decrease, in a dose-dependent manner, the food intake in fasted mice and have similar effects in comparable doses as centrally administered natural PrRP31, these effects are, however, stronger and longer lasting. Lipidation of an effective anorexigenic neuropeptide PrRP induces a central effect after peripheral administration and thus makes the lipidated analogs of PrRP a promising anti-obesity drug.Type: ApplicationFiled: July 11, 2013Publication date: June 25, 2015Inventors: Lenka Maletinska, Blanka Zelezna, Miroslava Blechova, Andrea Spolcova